Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints by unknown
1 3
Cancer Immunol Immunother (2017) 66:91–102
DOI 10.1007/s00262-016-1922-6
ORIGINAL ARTICLE
Phase I–II study of lenalidomide and alemtuzumab in refractory 
chronic lymphocytic leukemia (CLL): effects on T cells 
and immune checkpoints
Maria Winqvist1,2 · Fariba Mozaffari2 · Marzia Palma1,2 · Sandra Eketorp Sylvan2 · 
Lotta Hansson1,2 · Håkan Mellstedt2 · Anders Österborg1,2 · Jeanette Lundin1,2 
Received: 29 June 2016 / Accepted: 27 October 2016 / Published online: 4 November 2016 
© The Author(s) 2016. This article is published with open access at Springerlink.com
was accompanied by significant upregulation of HLA-DR 
after addition of alemtuzumab. Antigen-experienced cells 
increased at week 4 as the frequency of effector memory 
cells increased in the CD8+ subset (p < 0.003), while 
effector cells decreased in both the CD8+ and CD4+ sub-
sets (p < 0.0001 and p < 0.01). The Th1/Th2 balance was 
unchanged at week 4 but shifted toward a Th2 profile after 
combination therapy. At end of treatment, the frequency of 
Th17 and regulatory T cells was reduced (p < 0.01), naïve 
T cells decreased, and effector memory T cells increased 
(p < 0.05 and p < 0.01). Granzyme B+ T cells increased at 
30-week follow-up (p < 0.05). PD-1 expression was unaf-
fected. In conclusion, low-dose lenalidomide and alemtu-
zumab induced major perturbations of T cells, including 
increased proliferative activity and cytotoxic potential.
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Abstract This phase I–II study explored safety, immu-
nomodulatory and clinical effects of lenalidomide (weeks 
1–16) and alemtuzumab (weeks 5–16) in 23 patients with 
refractory chronic lymphocytic leukemia. Most patients 
had Rai stage III/IV disease and were heavily pretreated 
(median 4 prior therapies), and 61% had del(17p)/del(11q). 
Eleven of 19 evaluable patients (58%) responded, with a 
median response duration of 12 months (1–29+); time to 
progression was short in non-responders. Lenalidomide 
had a narrow therapeutic dose range, 2.5 mg/day was not 
efficient, and maximum tolerated dose was 5 mg/day. 
Grade 3–4 neutropenia and thrombocytopenia occurred 
in 84 and 55%, 30% had febrile neutropenia, and CMV-
reactivation requiring valganciclovir occurred in 30% of 
patients. The frequency of proliferating (Ki67+) CD8+ T 
cells was increased at week 4, with further increase in both 
the CD4+ and CD8+ subsets (p < 0.01 and <0.05), which 
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Introduction
Chronic lymphocytic leukemia (CLL) is associated with 
impaired immune functions resulting in increased risk 
of infections and secondary tumors. Patients often have 
hypogammaglobulinemia and abnormalities in T and NK 
cells. T cell dysfunctions are due to several factors, such as 
defective immunological synapse formation [1], impaired 
cell cytotoxicity [2] and imbalance in cell subsets [3, 4].
Lenalidomide is an immunomodulatory drug which has 
shown anti-tumor activity in patients with relapsed and/or 
refractory CLL, achieving an overall response rate (ORR) 
of 32–47% [5–7]. The most prominent side effects of lena-
lidomide in CLL are neutropenia and tumor flare reaction 
(TFR), with a dose-dependent risk of tumor lysis syndrome 
[6].
The mechanisms of action for lenalidomide in CLL are 
not entirely understood, but might include a direct tumor 
cell killing effect, immune modulation and alteration of 
the tumor microenvironment. Altered cytokine levels, 
upregulation of co-stimulatory molecules on CLL cells, 
normalized balance of T cell subsets and improved NK 
and T cell function have been reported in CLL patients 
treated with lenalidomide (reviewed in [8]). Moreover, 
immunomodulatory drugs reduced the number of regula-
tory T cells (Tregs) [9, 10], which are usually increased in 
patients with advanced-stage CLL [4, 9, 11] and expanded 
pro-inflammatory type 17 T helper (Th17) cells [10]. Fur-
thermore, immunomodulatory drugs induced T cell activa-
tion, proliferation and cytokine production in vitro without 
mitogenic activity [12, 13], but by a co-stimulatory effect 
[13, 14]. In vitro studies have also shown that lenalidomide 
may improve T cell functions by repairing the defective 
immunological synapse formation with CLL cells [15]. 
In vivo, lenalidomide treatment increased the number of 
CD8+CD69+ cells as well as IFN-γ-producing CD8+ cells, 
indicating an enhanced cytotoxic activity [10, 16]. Lenalid-
omide also induced production of IL-2 and IFN-γ in vivo, 
mediating a shift toward a type 1 T helper (Th1) cells pro-
file [17].
T cell activation through the TCR is regulated by a 
number of co-stimulatory and inhibitory signals, includ-
ing immune checkpoint receptors. This ultimately controls 
T cell activation in lymph nodes and effector responses in 
peripheral tissues. In particular, the immune checkpoint 
receptor PD-1 is induced on activated T cells, and once 
bound to the ligands, PD-L1 or PD-L2, expressed on tumor 
cells or cells in the tumor microenvironment, reduces TCR 
signaling [18].
T cells in CLL patients displayed a high PD-1 expres-
sion [2, 4, 19], and chemotherapy seemed to increase the 
proportion of CD4+PD-1+. This increase could be reversed 
by lenalidomide treatment [20]. Regarding the expression 
of the ligand PD-L1 on CLL cells, results are conflicting 
[4, 15, 19]. CTLA-4 is another immune checkpoint mol-
ecule transiently expressed on activated T cells [21] inhibit-
ing T cell activation. It has been reported that lenalidomide 
could overcome the inhibitory effect of CTLA-4 on T cell 
responses against the Epstein–Barr virus in vitro [14]. The 
expression profile of CTLA-4 on T cells from CLL patients 
has shown varying results [2, 4, 22].
Alemtuzumab is a humanized CD52 mAb that induced 
a response rate of 30–40% in relapsed/refractory CLL 
patients [23, 24]. Even though no longer approved for CLL 
but re-launched in multiple sclerosis, it is available through 
a free access program for CLL and other patients with an 
unmet need. Antibody-dependent cellular cytotoxicity, 
mainly induced by NK cells, is supposed to be an impor-
tant effector function of alemtuzumab, but also depleting 
immune cells leading to an increased risk of opportunistic 
and other infections.
The rationale for combining lenalidomide with alem-
tuzumab in the present trial was based on the assumption 
that lenalidomide might potentiate the antitumor activity of 
alemtuzumab by stimulating NK cell-mediated antibody-
dependent cellular cytotoxicity and activate T cells to coun-
teract the alemtuzumab-induced negative effect on T cells. 
Moreover, a synergistic effect might be expected, as the 
two drugs may have preferential effects in different disease 
compartments, i.e., alemtuzumab mostly on bone marrow 
and peripheral blood and lenalidomide mainly on lymph 
nodes, even though late responses on lenalidomide may 
occur in the bone marrow.
Results of a phase I study, in which 12 refractory CLL 
patients were included, have previously been reported [25]. 
In the present report, the complete analysis of totally 23 
patients is described, with a focus on analysis of changes 
in T cell subsets, including immune checkpoints as well as 
cell activation, proliferation and cytotoxic markers.
Materials and methods
Study population and eligibility criteria
The study was conducted according to the Declaration of 
Helsinki. Informed consent was obtained from all individ-
ual participants included in the study. The study was regis-
tered at clinical trials.gov and was approved by the Swedish 
Medical Products Agency (EudraCT number 2007-007434-
20) and the regional ethics committee. Patients with chemo-
therapy-refractory CLL or judged ineligible for chemother-
apy due to, for example, del(17p)/TP53 mutation or severe 
cytopenia were included in the study. The following criteria 
should be fulfilled as well: neutrophils ≥0.5 × 109/L, plate-
lets ≥25 × 109/L, creatinine ≤177 µmol/L, total bilirubin 
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≤26 µmol/L and Eastern Cooperative Oncology Group 
(ECOG) performance status ≤2.
Treatment schedule
Lenalidomide was given continuously as a single agent 
for weeks 1–4 at a starting dose of 2.5 mg/day in patients 
1–6 and 5 mg/day in patients 7–23 [25]. Alemtuzumab was 
added at week 5 (30 mg s.c. three times a week), and lena-
lidomide was then escalated stepwise (5–10–15 mg/day) 
depending on tolerability. Maximum treatment period was 
16 weeks of lenalidomide and 12 weeks of alemtuzumab.
Prophylaxis for tumor lysis syndrome and TFR was pro-
vided by proper hydration, allopurinol given 3 days before 
start of lenalidomide, as well as 10 mg of prednisone/day 
during the first week of treatment and at dose escalations. 
All patients received infection prophylaxis with cotrimox-
azole, valaciclovir and G-CSF (300 µg s.c. three times a 
week to normal granulocyte count). CMV monitoring was 
not performed, although CMV-PCR test was carried out in 
case of unexplained fever.
Assessments
Response evaluation was based on the 2008 International 
Workshop on Chronic Lymphocytic Leukemia (iwCLL) 
criteria [26]. Patients were evaluated with computed 
tomography scan at the end of treatment as well as bone 
marrow biopsies at week 12 and at the end of treatment. 
Treatment toxicity was evaluated using National Cancer 
Institute (NCI) Common Terminology Criteria for Adverse 
Events v3.0 except for anemia, thrombocytopenia and neu-
tropenia which were graded according to the grading scale 
for hematological toxicity in CLL studies [26]. Maximum 
tolerated dose (MTD) was defined as the dose that caused 
dose-limiting toxicity in less than one-third of the patients.
Flow cytometric analysis of whole blood lymphocytes
After lysis of red blood cells, cells were washed, resus-
pended in BD FACSFlow (BD Biosciences, San Diego, 
CA, USA) and stained according to the manufacturer’s rec-
ommendation using fluorochrome-coupled antibodies for 
CD19, CD3, CD4, CD8, CD16, CD56, CD52, CD45RA, 
human leukocyte antigen–antigen D related (HLA-DR) 
and C-C motif chemokine receptor (CCR) 7 (Supplemen-
tary Table 1). After incubation and washing, cells were 
resuspended in FACSFlow and analyzed by flow cytom-
etry using a FACSCanto II flow cytometer and analyzed 
by FACSDiva version 6.1.3 (BD Biosciences) or Infinicyt 
(Cytognos S.L., Salamanca, Spain).
Flow cytometric analysis of PBMC
PBMC were isolated from heparinized blood by density 
gradient centrifugation on a Ficoll-Hypaque (GE Health-
care, Uppsala, Sweden), washed twice with Dulbecco’s 
phosphate-buffered saline (0.9%) (Gibco, Life Technolo-
gies, Carlsbad, CA, USA). Cells were freshly used or 
stored in liquid nitrogen until use.
PBMC were then washed with CSB (BioLegend, San 
Diego, CA, USA) and stained for PD-1, CTLA-4, PD-L1, 
CCR6, C-X-C motif chemokine receptor (CXCR) 3, 
CD25, human leukocyte antigen–antigen D related (HLA-
DR) (Supplementary Table 1) and the appropriate isotype 
controls. After incubation for surface staining and wash-
ing, cells were resuspended in CSB and flow cytometric 
analysis was done by FACSCanto II flow cytometer (BD 
Biosciences).
For intracellular staining, cells were resuspended in 
fixation/permeabilization buffer, incubated for 30 min at 
4 °C and washed with permeabilization buffer (eBiosci-
ence). Antibodies (FOXp3, granzyme B, perforin, Ki67) 
were added to the resuspended cells and incubated for 
30 min at room temperature. Excess of antibodies was 
removed by washing twice with permeabilization buffer. 
The cells were then resuspended in CSB and analyzed 
by flow cytometry using a FACSCanto II flow cytometer 
and analyzed by the FACSDiva version 6.1.3 (BD Bio-
sciences) or the FlowJo version 8.8.2 (TreeStar, Ashland, 
OR, USA) softwares.
Statistical methods
Statistical analyses were performed using GraphPad Prism 
6.0 and SPSS 23.0. Comparison of marker expression at 
different time points was done with the Wilcoxon signed-
rank test for related samples. All tests were two-sided and 
p < 0.05 was considered significant. Survival analysis was 
done with the Kaplan–Meier method.
Results
Patients
Clinical characteristics of the patients are shown in Table 1. 
Median age was 69 years (range 61–85); 70% had Rai 
stage III/IV, 48% bulky disease (lymphadenopathy >5 cm), 
61% 17p and/or 11q deletion and 73% an unmutated Ig 
heavy chain variable (IgHV) gene. Patients were heavily 
pretreated having received a median of 4 prior therapies 
(range 1–7). Three patients had previous allo-SCT.
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Dose and MTD
The first six patients received a starting dose of 2.5 mg 
lenalidomide/day. Four of these patients progressed early, 
and the dose was considered ineffective in advanced-phase 
progressive CLL [25]. After an amendment, the subsequent 
17 patients received a starting dose of 5 mg/day. Median 
length of lenalidomide therapy was 12 weeks (range 0–16) 
and for alemtuzumab 10 weeks (range 0–12). Eleven 
patients (48%) completed all 16 weeks of lenalidomide and 
the 12 weeks of alemtuzumab therapy. MTD of lenalido-
mide, in combination with alemtuzumab, was 5 mg/day. 
Only two patients tolerated a lenalidomide dose of 10 mg/
day for more than 4 weeks, and no patient reached a dose 
of 15 mg/day. The most common dose-limiting toxicity 
was grade 3–4 neutropenia (15/17 of patients).
Efficacy
Four patients discontinued lenalidomide within 8 weeks 
due to causes other than disease progression. In one patient, 
the drug was withdrawn after two doses due to rapidly 
deteriorating general condition. Three patients stopped 
treatment after 3, 4 and 7 weeks, respectively, for various 
medical reasons (exfoliative dermatitis, legionella pneumo-
nia and other malignancy, respectively). The ORR in the 
intention-to-treat population was 48% (11/23) including 
two complete responses and nine partial responses. When 
excluding the four above-mentioned patients, ORR was 
58% (11/19). Responding patients received a median total 
lenalidomide dose of 520 mg (range 42–810 mg), and non-
responders received a median total dose of 177 mg (range 
50–650 mg).
Three patients were excluded from the analysis of pro-
gression-free survival, response duration and time to next 
treatment since after study completion they received either 
donor lymphocyte infusion (two patients) or allo-SCT (one 
patient). Median progression-free survival was 6 months 
(range 0–37+ months) (Supplementary Fig. 1) with five 
patients having a progression-free survival exceeding 
12 months. Median overall survival (OS) was 17 months 
(0–65+) (Supplementary Fig. 1). All but one of the sur-
viving patients are currently on treatment with ibrutinib or 
idelalisib.
Median response duration time of the eight responding 
patients was 12 months (range: 1–29+ months) (Supple-
mentary Fig. 1) and median time to treatment failure (next 
treatment or death) 18 months (range 3–52+ months).
Toxicity
The most common grade 3–4 adverse events were hema-
tological: neutropenia (84%) and thrombocytopenia (55%). 
No patient developed anemia ≥grade 3. The most common 
non-hematological grade 3–4 adverse events were febrile 
neutropenia (n = 7), pneumonia (n = 5), CMV-reactivation 
(n = 2), thrombosis (n = 2) and fever of unknown origin 
(n = 2). CMV-reactivation requiring valganciclovir therapy 
occurred in seven patients (30%).
Seven patients (30%) developed transient TFR (grade I–
II). Six of these responded to treatment, including five par-
tial responses and one complete response. The only patient 
with TFR who did not respond discontinued treatment early 
due to legionella pneumonia.
Immune responses
T cells, NK cells and Natural killer T (NKT) cells were 
markedly reduced by the combination treatment
After 4 weeks of single-agent lenalidomide treatment, no 
statistically significant changes were observed in the num-
bers of CD4+ T cells, CD8+ T cells, NK cells and NKT 
cells. After adding alemtuzumab, all the lymphoid sub-
sets decreased dramatically at week 16 and remained low 
in most patients at follow-up (weeks 30 and 45) (Fig. 1). 
The median numbers of CD4+ and CD8+ T cells were 157 
Table 1  Patient characteristics (n = 23)
Median (range) %




















Lymph nodes >5 cm 48
Unmutated IgHV gene 73
Refractory to fludarabine or bendamustine 56
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and 59 cells/µL at week 16 (end of treatment), 297 and 321 
cells/µL at week 30, and 249 and 392 cells/µL at week 45, 
respectively (Fig. 1a, b).
The proportion of CD52− T cells increased during 
treatment. At baseline, the number of CD52−CD3+ cells 
was low (median 18 cells/µL), whereas the number of 
CD52+CD3+ cells was high (median 1828 cells/µL). At the 
end of treatment, the frequency was reversed with CD52− 
cells comprising more than 85% of all T cells. Also, total 
CD52− T cell numbers increased during treatment (median 
292, 544 and 343 cells/µL at weeks 16, 30 and 45, respec-
tively) (data not shown).
Activated (HLA‑DR+) and proliferating (Ki67+) T cells 
increased during lenalidomide treatment
After 4 weeks of lenalidomide treatment, no significant 
increase was observed in the frequency of Ki67+CD4+ 
cells (Fig. 2a), while the frequency of Ki67+CD8+ cells 
increased from 2.3% (median) (range 0.8–16.9) at baseline 
to 3.8% (range 0.8–27.0) at week 4 (p < 0.05) (Fig. 2b). At 
the end of treatment (week 16), Ki67+ cells among both the 
CD4+ and CD8+ subsets had further increased (median 6.2 
and 7.0%, respectively, p < 0.006 and p < 0.05) (Fig. 2a, 
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Fig. 1  Absolute numbers of a CD4+, b CD8+, c NK and d NKT 
cells at baseline, during and after therapy. Lenalidomide was admin-
istered on weeks 1–16 and alemtuzumab weeks 5–16. Median num-
ber of cells/µL at each time point is depicted under each figure. 
* p < 0.05, ** p < 0.01, *** p < 0.001
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preliminarily reported earlier [25], a significant increase 
was observed in the frequency of activated (HLA-DR+) 
T cells after single-agent lenalidomide treatment. The 
frequency increased further during the combination ther-
apy, and HLA-DR+ cells increased from 25% at baseline 
to 82% at week 16 within the CD4+ subset (p = 0.0009) 
and from 33 to 89% in the CD8+ subset (p = 0.0017) 
(Fig. 2c, d). Similar to Ki67+ cells, HLA-DR+ expression 
gradually normalized during the non-treatment follow-up 
period. There was no significant change in the proportion 
of T cells expressing perforin/granzyme B during treat-
ment with lenalidomide alone. The combination treatment 
significantly increased the proportion of granzyme B+ cells 
within CD4+ (p < 0.05) as well as CD8+ T cells (p < 0.05) 
from baseline until week 30 of follow-up (data not shown).
A shift toward a type 2 T helper (Th2) cells profile 
and reduced frequency of Th17 and Tregs were observed 
during combination therapy
T helper subpopulations were defined by CCR6 and 
CXCR3 expression as Th1 (CCR6−/CXCR3+), Th2 
(CCR6−/CXCR3−) and Th17 (CCR6+/CXCR3−) cells. 
Tregs were defined as CD4
+, CD25high and FOXp3+. The 
Th1/Th2 balance (Fig. 3) was unaffected by lenalidomide 
therapy alone (weeks 1–4), but then the frequency of Th1 
cells decreased from 50% (median) (range 7–81%) at 
baseline to 6% (range 0–79%) at week 16 (not significant) 
(Fig. 3a). The proportion of Th2 cells increased from 32% 
(median) (10–82%) at baseline to 88% (8–99%) at the end 









































































Fig. 2  Percentage of a Ki67+CD4+, b Ki67+CD8+, c HLA-DR+CD4+ and d HLA-DR+CD8+ cells at baseline, during and after therapy. Lena-
lidomide was administered on weeks 1–16 and alemtuzumab weeks 5–16. * p < 0.05, ** p < 0.01, *** p < 0.001
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Th2 cells remained high during follow-up (Fig. 3b). The 
median percentage of Th17 cells decreased significantly 
during combination therapy from 7% at baseline to 2.2% 
at week 16 (p = 0.004) (Fig. 3c). The decrease in Tregs 
observed in part I of the study [25] was confirmed in the 
present extended analysis (p = 0.003) (Fig. 3d).
A shift in memory T cell subsets was observed 
during therapy
CD4+ and CD8+ memory cell subsets were identified 
by CCR7 and CD45RA expression. The percentages of 
naïve (CD45RA+/CCR7+), central memory (CD45RA−/
CCR7+), effector memory (CD45RA−/CCR7−) and effec-
tor (CD45RA+/CCR7−) cells were determined. The results 
for effector memory cells are shown in Fig. 4a and b. After 
4 weeks of lenalidomide treatment, the percentage of effec-
tor memory CD8+ cells increased (p < 0.003) (Fig. 4b), 
while the percentage of effector cells (CD4+ and CD8+) 
decreased (p < 0.01 and p < 0.0001) (Fig. 4c, d). At the 
end of the combination treatment (week 16), the percent-
ages of naïve CD4+ and CD8+ T cells decreased (p < 0.05) 
(Fig. 4e, f). The percentage of effector memory cells 
increased significantly within both CD4+ and CD8+ cells 
(p < 0.01) (Fig. 4a, b). Central memory T cells appeared to 
be less affected (Fig. 4g, h).
PD‑1 expression remained unaffected by treatment
The percentage of PD-1+ cells before treatment was 53% 
(median) in the CD4+ cells and 15% (median) in the CD8+ 
cells. The proportion of PD-1-expressing cells remained 
unchanged in both CD4+ (Fig. 5a) and CD8+ (Fig. 5b) T 
cells during lenalidomide, combination therapy and fol-
low-up. No expression of PD-L1 was detected on freshly 
isolated CLL cells at study start or during therapy. Neither 
was CTLA-4 surface expression on T cells observed at 



























































Fig. 3  Percentage of a Th1, b Th2, c Th17 and d Treg cells at baseline, during and after therapy. Lenalidomide was administered on weeks 1–16 
and alemtuzumab weeks 5–16. * p < 0.05, ** p < 0.01, *** p < 0.001
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Discussion
Until recently, patients with high-risk CLL [refractory/
relapsed or with del(17p)/TP53 mutation] had a very poor 
prognosis [27, 28]. New drugs, such as ibrutinib, venetoclax 
and idelalisib, which were not available for CLL patients at 
the initiation of this study, are now changing the landscape 
of CLL treatment proving to be highly effective in relapsed 
or refractory patients even with high-risk cytogenetics 
[29–32]. Despite the impressive clinical results obtained 
by, e.g., ibrutinib, patients with del(17p)/TP53 mutation, 
still relapse and have a relatively short OS [33, 34]. Patients 
who relapse after treatment with the new drugs or do not 
tolerate them may still need the previous generation of 
anti-CLL agents such as alemtuzumab (currently available 
through a free access program) or other active agents such 
as lenalidomide.
Lenalidomide as a single agent has shown to be active in 
CLL [5–7]. It is explored as maintenance therapy for CLL 
in an ongoing phase III trial and in combination with other 
agents in phase II studies [35–40].
We report here the final results of a phase I–II trial 
exploring safety and clinical efficacy of lenalidomide in 
combination with alemtuzumab in advanced-stage CLL, 
with a focus on the effects of the two drugs on T cell 
subsets.
As for part I of the study [25], the present full study 
report confirmed an acceptable safety profile of the combi-
nation. However, grade 3–4 infections appeared to be more 
frequent than that reported in previous studies in which 
each drug was used separately [6, 23, 24]. The incidence 
of symptomatic CMV-reactivation (30%) was similar to 
that reported with alemtuzumab alone. Thus, the immune-
enhancing potential of lenalidomide seemed not to translate 
into a reduced risk of infections. Higher doses of lenalido-
mide might have been more effective, but dose escalation 
was hindered by the low MTD of only 5 mg/day. Nota-
bly, grade 3–4 neutropenia occurred in more than 80% of 
patients, despite the use of G-CSF prophylaxis. This is in 
contrast to most previous studies reporting a tolerated dose 
of 10 mg [8, 41], even though one study noted that lena-
lidomide in heavily pretreated patients was feasible only at 
a dose of 5 mg [42]. Despite the low dose of lenalidomide, 
ORR of our drug combination appeared to be clinically 
meaningful. More than half of our elderly poor-prognosis 
patients with advanced-stage CLL responded and those 
who tolerated therapy reached a reasonably long response 
duration time. However, the results of the present study 
should be interpreted with caution as the number of patients 
was low.
Effects of lenalidomide indicated that immune stimula-
tory effects on T cells started early in spite of the low dose 
of lenalidomide. Not only activation (HLA-DR expres-
sion) was observed, but also an increased proportion of 
Ki67+CD8+ T cells at week 4. This was accompanied by 
a relative increase in CD8+ effector memory cells and a 
decrease in CD8+ effector cells, indicating an increase in 
antigen-experienced (CD45RA−) CD8+ cells which is in 
line with what have been observed in multiple myeloma 
patients [43, 44].
A limitation of our study is the marked T cell-depleting 
effect of alemtuzumab, which complicated the analysis of 
total T cell subsets. We therefore focused on the relative 
changes within major subsets, as the functions of remain-
ing T cells in blood after alemtuzumab therapy are likely 
to be of importance for the immune status of the patients. 
As described previously [45], most post-treatment T cells 
were CD52−. The total CD4+ T cell numbers at the end of 
the combination treatment are slightly higher in the current 
study than after treatment with alemtuzumab alone [23].
At week 16, i.e., at the end of treatment, an increase in 
the percentage of Th2 cells was noted accompanied by a 
decrease in Treg, Th17 and naïve T cells. This is in contrast 
to previous results, suggesting that lenalidomide could 
cause a shift from Th2 to Th1 cells [17]. Our observations 
are most likely attributed to alemtuzumab therapy, similar 
to the relative increase in Th2 cells during alemtuzumab 
treatment seen in patients with multiple sclerosis [46]. Fur-
thermore, an increase in the proportion of granzyme B+ T 
cells was noted, implying an enhanced cytotoxic potential.
PD-1 binds through its ligands on immune cells and tar-
get cells countering TCR-induced T cell proliferation, cyto-
toxicity and cytokine production [18]. Studies in CLL have 
suggested that lenalidomide might affect the expression of 
the PD-1/PD-L1 receptors [15, 20]. However, we were not 
able to confirm those findings, which is in line with a study 
in multiple myeloma patients where no difference in the 
frequency of CD8+PD1+ cells could be noted comparing 
untreated and lenalidomide-treated patients [43].
Moreover, we did not find PD-L1 expression on CLL 
cells, which is in contrast to previous studies [15, 19]. 
However, preliminary results from a phase II study apply-
ing PD-1 blockade in relapsed/refractory CLL, including 
patients with Richter’s transformation, showed promising 
clinical activity on the transformed cells, but not against the 
untransformed CLL clone [47], which might support the 
absence of PD-L1 on the CLL clone.
Fig. 4  Percentage of T cell subpopulations a effector memory CD4+, 
b effector memory CD8+, c effector CD4+, d effector CD8+, e naïve 
CD4+, f naïve CD8+, g central memory CD4+, h central memory 
CD8+ at baseline, during and after therapy. Lenalidomide was admin-
istered on weeks 1–16 and alemtuzumab weeks 5–16. * p < 0.05, 
** p < 0.01, *** p < 0.001
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In conclusion, our study showed that lenalidomide 
alone or in combination with alemtuzumab induced vari-
ous immunomodulatory effects on T cells in CLL patients. 
Further studies on lenalidomide as an immune-enhancing 
agent in CLL and other disorders are warranted.
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